CYP3A4 and CYP3A5 Genes in Cyclophosphamide-treated Chronic Lymphocytic Leukemia Patients: A Pharmacogenetics Study
Frontiers in Bioscience-Scholar · 2025
DOI: 10.31083/fbs36269 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Bioscience-Scholar, 2025. Verfasst von Heba M Elmaraghy und 7 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pathology Department, Faculty of Medicine, Ain Shams University, 11566 Cairo, Egypt. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP3A, Cyclophosphamide, Leukemia, Lymphocytic, Chronic, B-Cell. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Approximately 75% of drug metabolism in clinical settings is attributed to cytochrome P450 enzymes. This study aimed to assess the effects of the CYP3A4*1B and CYP3A5*3 genetic variations on the clinical results of individuals with chronic lymphocytic leukemia (CLL) following cyclophosphamide treatment. Furthermore, we aimed to ascertain how well the inflammatory condition affects the therapeutic response.
Methods
CYP3A4*1B and CYP3A5*3 polymorphisms were examined in 150 Egyptian CLL patients using allele-specific amplification (ASA)-polymerase chain reaction (PCR); serum interleukin 6 (IL-6) and tumor necrosis factor-alpha (TNF-α) levels were also measured to assess the non-genetic inflammatory effect on CYP3A4 and CYP3A5 genes. Patients further received chemotherapy and were subsequently followed up.
Results
The allelic frequencies of the CYP3A4*1B gene were (74.3% A-allele vs. 25.7% G-allele), and for CYP3A5*3, these frequencies were (73.4% A-allele vs. 26.6% G-allele). Patients with the CYP3A4*1B and CYP3A5*3 genes, or both variants, were less likely to respond than the normal patients (p < 0.001). Regarding the non-genetic inflammatory effect, patients in the response group who achieved partial remission were characterized by higher IL-6 and TNF-α values than those who achieved complete remission (p < 0.001), and patients in the non-response group who had a progressive disease were characterized by higher IL-6 and TNF-α values than those who had a stable disease (p < 0.001).
Conclusion
CYP3A4*1B and CYP3A5*3 variants could be helpful indicators in predicting the response to cyclophosphamide chemotherapy. CYP3A4 and CYP3A5 variability should be factored into personalized medicine, which attempts to optimize drug dosing for individual patients by considering genetic and non-genetic factors affecting the response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pathology Department, Faculty of Medicine, Ain Shams University, 11566 Cairo, Egypt.
- Division of Biochemistry, Chemistry Department, Faculty of Science, Mansoura University, 35511 Mansoura, Egypt.
- Hematology and Immunology Depertment, Al-Qunfudah Faculty of Medicine, Umm Al-Qura University, 21955 Al-Qunfudah, Makkah, Saudi Arabia.
- Medical Pharmacology Department, Faculty of Medicine, Cairo University, 11562 Cairo, Egypt.
- Genetics Department, Mansoura Children's Hospital, 35516 Mansoura, Egypt.
- Medical Oncology Unit, Oncology Center Mansoura University, 35516 Mansoura, Egypt.
Zitieren
APA
Elmaraghy, H. M., Al-Adl, M., Saifeldein, E. R., Elashmony, S. M., Youssef, M. M., El-Said, A., Refaat, S., & Mohammed, A. E. (2025). CYP3A4 and CYP3A5 Genes in Cyclophosphamide-treated Chronic Lymphocytic Leukemia Patients: A Pharmacogenetics Study. Frontiers in Bioscience-Scholar. https://doi.org/10.31083/fbs36269
Vancouver
Elmaraghy HM, Al-Adl M, Saifeldein ER, Elashmony SM, Youssef MM, El-Said A, et al. CYP3A4 and CYP3A5 Genes in Cyclophosphamide-treated Chronic Lymphocytic Leukemia Patients: A Pharmacogenetics Study. Frontiers in Bioscience-Scholar. 2025. doi:10.31083/fbs36269
BibTeX
@article{Elmaraghy2025,
author = {Elmaraghy, Heba M and Al-Adl, Menna and Saifeldein, Eman R and Elashmony, Sahar M and Youssef, Magdy M and El-Said, Afaf and Refaat, Sherif and Mohammed, Abdallah E},
title = {CYP3A4 and CYP3A5 Genes in Cyclophosphamide-treated Chronic Lymphocytic Leukemia Patients: A Pharmacogenetics Study},
journal = {Frontiers in Bioscience-Scholar},
year = {2025},
doi = {10.31083/fbs36269}
}
EUVIMED